How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

242 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01422720 Recruitment Status : Completed First Posted : August 24, 2011 Results

2011 Clinical Trials

102. Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study.

Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. This study investigated the effect of eslicarbazepine acetate (ESL) on cardiac repolarization in healthy adult volunteers. A randomized, placebo/active-controlled, 4-period crossover study was conducted in 67 participants. In 3 periods, participants received once-daily doses of ESL 1200 mg, ESL 2400 mg, and placebo for 5 days; in 1 period, participants received placebo on days 1 to 4 and a 400-mg

2011 Journal of clinical pharmacology

103. Eslicarbazepine Acetate: A Well-Kept Secret? (PubMed)

Eslicarbazepine Acetate: A Well-Kept Secret? 20126330 2010 06 28 2018 11 13 1535-7511 10 1 2010 Jan Epilepsy currents Epilepsy Curr Eslicarbazepine acetate: a well-kept secret? 7-8 10.1111/j.1535-7511.2009.01337.x Ben-Menachem Elinor E eng Comment Journal Article United States Epilepsy Curr 101135954 1535-7511 Epilepsia. 2009 Mar;50(3):454-63 19243424 2010 2 4 6 0 2010 2 4 6 0 2010 2 4 6 1 ppublish 20126330 10.1111/j.1535-7511.2009.01337.x PMC2812714 Lancet. 2007 Mar 24;369(9566):1000-15

Full Text available with Trip Pro

2010 Epilepsy Currents

104. Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01091662 Recruitment Status

2010 Clinical Trials

105. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. (PubMed)

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Combination therapy is frequently required in the management of epilepsy. The primary objective of this study was to investigate the pharmacokinetic interaction between eslicarbazepine acetate (ESL) 1200 mg once daily and topiramate (TPM) 200 mg once daily in healthy subjects.Multiple-dose, open-label, one-sequence study in two parallel groups of 16 healthy male volunteers. After an 8-day (...) treatment with ESL (Group A) or TPM (Group B), ESL and TPM were co-administered for 19 days. A bioequivalence approach based on a within-subject comparison was used to investigate a potential drug-drug interaction. End/start of treatment geometric mean ratios (GMR, %) and 90% confidence intervals (90% CI) were calculated for maximum plasma concentration (C(max)) and area under the plasma concentration-time curve over the dosing interval at steady-state (AUC(ss)) of eslicarbazepine (ESL major active

2010 Current medical research and opinion

106. Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01162460 Recruitment Status : Completed First

2010 Clinical Trials

107. Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Eslicarbazepine Acetate (...) ): Bial - Portela C S.A. Study Details Study Description Go to Brief Summary: The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment phase. Condition or disease Intervention/treatment Phase Painful Diabetic Neuropathy Drug: Eslicarbazepine acetate (BIA 2-093) Drug: Placebo Phase 3 Detailed Description: Diabetic neuropathic pain (DNP) is one of the most common complications

2010 Clinical Trials

108. Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Eslicarbazepine Acetate as Therapy (...) - Portela C S.A. Study Details Study Description Go to Brief Summary: The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment phase. Condition or disease Intervention/treatment Phase Post Herpetic Neuralgia Drug: Eslicarbazepine acetate (BIA 2-093) Drug: Placebo Phase 3 Detailed Description: Post-herpetic neuralgia (PHN) is a syndrome of intractable pain following an acute infection

2010 Clinical Trials

109. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. (PubMed)

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. To investigate the efficacy and safety of once-daily eslicarbazepine acetate (ESL) when used as add-on treatment in adults with > or = 4 partial-onset seizures per 4-week despite treatment with 1 to 3 antiepileptic drugs (AEDs).This double-blind, parallel-group, multicenter study consisted of an 8-week observational baseline period, after which patients were randomized to placebo (n=100) or once-daily ESL 400 (...) , blurred vision, and fatigue. The majority of AEs were of mild or moderate severity.Treatment with once-daily eslicarbazepine acetate 800 mg and 1200 mg was more effective than placebo and generally well tolerated in patients with partial-onset seizures refractory to treatment with 1 to 3 concomitant AEDs.Copyright 2010 Elsevier B.V. All rights reserved.

2010 Epilepsy research Controlled trial quality: uncertain

110. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. (PubMed)

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. The results of two single-blind studies conducted to evaluate the cognitive and psychomotor effects of eslicarbazepine acetate and oxcarbazepine following single and repeated administration in healthy volunteers are reported. The cognitive and psychomotor evaluation consisted of several computerized and paper-and-pencil measures. Eslicarbazepine acetate and oxcarbazepine had similar (...) overall cognitive profiles and did not cause clinically relevant cognitive impairment. The incidence of adverse events was lower with eslicarbazepine acetate than with oxcarbazepine.Copyright 2010. Published by Elsevier Inc.

2010 Epilepsy & behavior : E&B Controlled trial quality: uncertain

111. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. (PubMed)

Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. To evaluate the long-term efficacy and safety of once daily eslicarbazepine acetate (ESL) as adjunctive therapy for partial-onset seizures in adults with epilepsy.One-year open-label treatment extension with ESL in patients who completed a placebo-controlled pivotal study (Epilepsia 2009; 50: 454-463). Starting dose was 800 mg once daily

Full Text available with Trip Pro

2010 Epilepsia Controlled trial quality: uncertain

113. Oxcarbazepine

of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for oxcarbazepine 1. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide (...) and oxcarbazepine Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized (...) , double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A CRD summary The authors concluded that antiepileptic drugs may cause neurological adverse events in patients with drug resistant epilepsy, which can limit their use and impair treatment success; higher doses of oxcarbazepine were associated

2018 Trip Latest and Greatest

114. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy

as monotherapy, and how does their efficacy and tolerability compare with those of older antiepileptic drugs (AEDs)? • Clobazam (CLB) • Lacosamide • Perampanel • Topiramate (TPM) • Eslicarbazepine • Lamotrigine (LTG) • Pregabalin (PGB) • Vigabatrin (VGB • Felbamate (FBM) • Levetiracetam (LEV) • Rufinamide • Zonisamide (ZNS) • Gabapentin (GBP) • Oxcarbazepine (OXC) • Tiagabine Recommendations for monotherapy in adults with new-onset epilepsy with focal epilepsy or unclassified tonic-clonic seizures Level (...) extrapolation of efficacy across populations and granted approval of eslicarbazepine and lacosamide (oral only for pediatric age group) as add-on or monotherapy for focal epilepsy in persons =4 years old and perampanel as monotherapy for focal epilepsy. FBM and VGB are not recommended in new-onset epilepsy for clinical use due to serious AEs, as there are other agents that are both safe and efficacious. This guideline was co-developed with the American Epilepsy Society. American Academy of Neurology, 201

2018 American Academy of Neurology

115. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy

) effective as adjunctive therapy in reducing seizure frequency? Level Recommendation* Level A For treatment-resistant adult focal epilepsy (TRAFE), immediate-release pregabalin (PGB) and perampanel (PER) are established as effective to reduce seizure frequency. Level B Lacosamide (LCM), eslicarbazepine (ESL), and extended-release topiramate use should also be considered to decrease seizure frequency in this population. Level A Vigabatrin (VGB) and rufinamide (RFN) should be considered established (...) effective in reducing seizure frequency when used as monotherapy? Level Recommendation Level C Eslicarbazepine use may be considered to decrease seizure frequency as monotherapy for TRAFE. Level U Data are insufficient to recommend the use of second- and the other third-generation AEDs as monotherapy in TRAFE. For adult and pediatric patients with TR generalized epilepsy (GE), are these AEDs effective in reducing seizure frequency when used as adjunctive therapy (compared with no adjunctive therapy

2018 American Academy of Neurology

116. Epilepsy in Pregnancy

, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate and eslicarbazepine) should be counselled about the risk of failure with some hormonal contraceptives. Women should be counselled that the efficacy of oral contraceptives (combined hormonal contraception, progestogen-only pills), transdermal patches, vaginal ring and progestogen-only implants may be affected if they are taking enzyme-inducing AEDs (e.g. carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine and eslicarbazepine (...) in the levetiracetam monotherapy group (0.7 per 100; 95% CI 0.19–2.51) than the polytherapy group (5.6 per 100, 95% CI 3.54–8.56). 10 There is insufficient evidence to provide robust estimates of risk of major congenital malformation for other AEDs in monotherapy such as eslicarbazepine, gabapentin, lacosamide, oxcarbazepine, perampanel, pregabalin, topiramate or zonisamide. The risk of recurrence for major congenital malformation was increased (16.8 per 100) in WWE with a previous child with major congenital

2016 Royal College of Obstetricians and Gynaecologists

117. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine

-B*15:02 frequency is much lower in Japanese ( >> DRESS) combined are most favorable for European populations, and they are estimated at 43% and 47, respectively. 31 Limited, if any, evidence exists to support an association between HLA-A*31:01 and hyper- sensitivity associated with other aromatic anticonvulsants, including lamotrigine, 32 oxcarbazepine, eslicarbazepine, phenytoin, fospheny- toin, and phenobarbital, and thus no recommendations can be given regarding the safety of these agents (...) ). These recommendations hold irrespective of the patient’s region of origin or ethnic group. For patients who are HLA-B*15:02 negative, carbamazepine or oxcarbazepine may be prescribed per standard guidelines. If a patient is carbamazepine-na€ ive or oxcarbazepine-na€ ive and HLA-B*15:02 positive, carbamazepine and oxcarbazepine should be avoided, respectively, due to the greater risk of SJS/TEN. Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, phenyt- oin, fosphenytoin, and phenobarbital, have

2017 Clinical Pharmacogenetics Implementation Consortium

118. Brivaracetam (Briviact) for use in the treatment of patients with refractory epilepsy

of licence extension: 11 July 2018 Comparator(s) The comparators included in the company submission are: • eslicarbazepine acetate (Zebinix ® ) • lacosamide (Vimpat ® ) • oxcarbazepine (Trileptal ® ) • zonisamide (Zonegran ® ) Limited submission details • The limited submission criteria were met based on a minor licence extension and anticipated minimal budgetary impact in NHS Wales Clinical effectiveness • Brivaracetam (Briviact ® ) has previously been recommended by the All Wales Medicines Strategy (...) 3387. Page 2 of 3 expected that brivaracetam would potentially displace lacosamide, zonisamide, oxcarbazepine or eslicarbazepine acetate (the latter three are licensed for children above 6 years of age). Brivaracetam is reported to be useful in people who have responded to levetiracetam but had behavioural or other side effects that have led to its cessation. • The paediatric licence extension was based on the extrapolation of efficacy data from clinical studies in patients aged 16 years and above

2019 All Wales Medicines Strategy Group

120. Contraception - emergency

-inducing drugs or who have taken them within the past 28 days. Table 1 lists some drugs that induce liver enzymes, and may decrease the efficacy of emergency hormonal contraception. Table 1. Drugs that induce liver enzymes. Drug class Drug Antiepileptics Carbamazepine, eslicarbazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, rufinamide, topiramate (weak inducer) Antibiotics Rifampicin (potent inducer), rifabutin Antiretrovirals Protease inhibitors: ritonavir, atazanavir, darunavir

2019 NICE Clinical Knowledge Summaries

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>